Home
Scholarly Works
Phase 1/2 Study of Treatment Response With...
Conference

Phase 1/2 Study of Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Patients with Thyroid Eye Disease (TED)

Authors

Turbin R; Douglas R; Ugradar S; Cockerham K; Schiffman J; Nijhawan N; O'Shaughnessy D; Summerfelt R; She A; Katz B

Volume

64

Publisher

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Publication Date

June 1, 2023

Name of conference

Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)

Conference place

LA, New Orleans

Conference start date

April 23, 2023

Conference end date

April 27, 2023

Conference proceedings

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Issue

8

ISSN

0146-0404

Labels

Fields of Research (FoR)

Contact the Experts team